Document Type

Article

Peer Reviewed

1

Publication Date

8-8-2017

NLM Title Abbreviation

Cell Rep

Journal/Book/Conference Title

Cell Reports

PubMed ID

28793252

DOI of Published Version

10.1016/j.celrep.2017.07.031

Start Page

1269

End Page

1277

Total Pages

9

Abstract

The human gut is colonized by a large number of microorganisms (∼1013 bacteria) that support various physiologic functions. A perturbation in the healthy gut microbiome might lead to the development of inflammatory diseases, such as multiple sclerosis (MS). Therefore, gut commensals might provide promising therapeutic options for treating MS and other diseases. We report the identification of human gut-derived commensal bacteria, Prevotella histicola, which can suppress experimental autoimmune encephalomyelitis (EAE) in a human leukocyte antigen (HLA) class II transgenic mouse model. P. histicola suppresses disease through the modulation of systemic immune responses. P. histicola challenge led to a decrease in pro-inflammatory Th1 and Th17 cells and an increase in the frequencies of CD4+FoxP3+ regulatory T cells, tolerogenic dendritic cells, and suppressive macrophages. Our study provides evidence that the administration of gut commensals may regulate a systemic immune response and may, therefore, have a possible role in treatment strategies for MS.

Keywords

OAfund, EAE; Prevotella histicola; demyelination; experimental autoimmune encephalomyelitis; gut microbiome; human commensal; immunomodulation; inflammation; multiple sclerosis; regulatory T cells

Granting or Sponsoring Agency

3M, Merck, Allergan, Infectious Diseases Society of America, National Institutes of Health (NS048357, GM092993, NS073684), European Regional Development Fund (FNUSA-ICRC CZ.1.05/1.1.00/02.0123), Hilton, Department of Defense (DOD) (W81XWH-10-1-0254), National Multiple Sclerosis Society (NMSS) (RG 5138A1/1T), BioFire, Check-Points, Curetis, Hutchison Biofilm Medical Solutions, Accelerate Diagnostics, The Medicines Company, ASM, USMLE, Up-to-Date, Infectious Diseases Board Review Course, NIH CTSA (RR024150, TR000135), Novartis Pharmaceuticals, Applebaum, Peterson, McNeilus Foundations

Grant Number

DOD W81XWH- 10-1-0254, NMSS RG 5138A1/1T, NIH GM092993, NS048357, NS073684, NIH CTSA RR024150 and TR000135, ERDF FNUSA-ICRC CZ.1.05/1.1.00/ 02.0123

Journal Article Version

Version of Record

Published Article/Book Citation

Cell Reports 20, 1269–1277

http://dx.doi.org/10.1016/j.celrep.2017.07.031

Rights

Copyright (c) 2017 The Authors

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.

Included in

Pathology Commons

Share

COinS
 

URL

http://ir.uiowa.edu/pathology_pubs/7